🔥Ph2 Peri-operative RASi (HRS-4642, G12D)+ GnP +/-adebrelimab (PD-L1)
➡️two cohorts n=60 #PDAC
➡️safety- mainly haem, none precluded surgery
➡️ORR 63% & 87%;MPR in 17%
➡️R0 resection rate 100%
✅6 mth EFS rate 87% & 96%
➡️100% ⬇️CA19.9; OS pending
@myESMO #ESMO26 @OncoAlert
